FDA Advances Drug Repurposing to Address Unmet Medical Needs
The FDA has begun soliciting public and stakeholder input regarding initiatives to advance drug repurposing for diseases and conditions with unmet medical needs.
Pharmaceutical manufacturers, clinical researchers, and regulatory departments involved in seeking new indications for existing or previously studied drug products.
This solicitation suggests an agency-wide interest in optimizing the utility of existing compounds. For regulatory teams, this may indicate a future shift toward more streamlined pathways or specific incentives for supplemental applications. It potentially signals a desire to address commercial or regulatory barriers that currently discourage sponsors from pursuing new indications for off-patent or older therapeutic agents.
Review internal pipelines for shelved or off-patent compounds that may align with current unmet needs. Monitor upcoming FDA listening sessions or dockets to provide feedback on barriers to repurposing, such as patent life or data requirements. Assessment of existing safety data for new indications may streamline future clinical strategies.
FDA announced it is soliciting input on efforts with respect to drug repurposing to help address unmet medical needs across a range of diseases and conditions.
Open in openFDA / FDA.gov